FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1054-1062 October 8, 1998 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Andrews, P. A. PubMed Citation

The objectives in caring for patients who are undergoing hemodialysis include providing sufficient dialysis, ensuring adequate nutrition, maintaining vascular access, correcting hormonal deficiencies, minimizing hospitalization, and prolonging life while enhancing its quality.

Dose of Hemodialysis

The dose of dialysis, which depends on the length of treatment, the type of dialyzer membrane, and solute clearance, is the most important modifiable determinant of survival in patients with end-stage renal disease who are receiving hemodialysis.^1,2,3,4,5 In the United States, the mean length of hemodialysis treatment is 3.5 hours three times a week and the mean rate of urea clearance is about 188 ml per minute.⁴ Prompted . . . [Full Text of this Article]

Vascular Access

Nutrition and Fluid Balance

Cardiovascular Problems

Ischemic Heart Disease

Congestive Heart Failure

Hypertension

Pericarditis

Hematologic Problems

Anemia

Increased Bleeding Tendency

Infections

Immunizations

Renal Osteodystrophy

Sexual Dysfunction and Pregnancy

Gastrointestinal Problems

Neurologic Problems

Special Issues

Diabetes Care

Acquired Immunodeficiency Syndrome

Hyperlipidemia

Rehabilitation

Depression

Perioperative Management

Cancer Screening

Noncompliance

Kidney Transplantation

Source Information

From the Renal Disease Division, Box 52, Department of Medicine, State University of New York Health Science Center at Brooklyn, 450 Clarkson Ave., Brooklyn, NY 11203, where reprint requests should be addressed to Dr. Ifudu.

References

Related Letters:

The Care of Patients Undergoing Hemodialysis
Andrews P. A., Korosi A., Sedlacek M., Slavcheva E., Fournier A., Morinière P., Pruna A., Knoll G., Curtis J., Ifudu O.
Extract | Full Text  
N Engl J Med 1999; 340:735-737, Mar 4, 1999. Correspondence

This article has been cited by other articles:

• Rocha, E., Soares, M., Valente, C., Nogueira, L., Bonomo, H. Jr, Godinho, M., Ismael, M., Valenca, R. V. R., Machado, J. E. S., Maccariello, E. (2009). Outcomes of critically ill patients with acute kidney injury and end-stage renal disease requiring renal replacement therapy: a case-control study. Nephrol Dial Transplant 24: 1925-1930 [Abstract] [Full Text]  
• Parra, E., Ramos, R., Betriu, A., Paniagua, J., Belart, M., Martinez, T. (2008). Effect of a quality improvement strategy on several haemodialysis outcomes. Nephrol Dial Transplant 23: 2943-2947 [Abstract] [Full Text]  
• (2004). Evidence-based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement. Am. J. Respir. Crit. Care Med. 170: 1247-1259 [Full Text]  
• Nagaoka, T, Takeyama, Y, Kanagawa, S, Sakagami, K, Mori, F, Yoshida, A (2004). Effect of haemodialysis on retinal circulation in patients with end stage renal disease. Br J Ophthalmol 88: 1026-1029 [Abstract] [Full Text]  
• Chan, C. T., Harvey, P. J., Picton, P., Pierratos, A., Miller, J. A., Floras, J. S. (2003). Short-Term Blood Pressure, Noradrenergic, and Vascular Effects of Nocturnal Home Hemodialysis. Hypertension 42: 925-931 [Abstract] [Full Text]  
• Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. M., Thadhani, R. (2003). Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy. NEJM 349: 446-456 [Abstract] [Full Text]  
• Yigla, M., Nakhoul, F., Sabag, A., Tov, N., Gorevich, B., Abassi, Z., Reisner, S. A. (2003). Pulmonary Hypertension in Patients With End-Stage Renal Disease. Chest 123: 1577-1582 [Abstract] [Full Text]  
• Nzerue, C. M., Jackson, E. (2000). Intractable life-threatening hyperkalaemia in a diabetic patient. Nephrol Dial Transplant 15: 113-114 [Full Text]  
• Szycher, M. (1999). End-Stage Renal Disease (ESRD) and Vascular Access Grafting: A Critical Review. J Biomater Appl 13: 297-350 [Abstract]  
• Andrews, P. A., Korosi, A., Sedlacek, M., Slavcheva, E., Fournier, A., Moriniere, P., Pruna, A., Knoll, G., Curtis, J., Ifudu, O. (1999). The Care of Patients Undergoing Hemodialysis. NEJM 340: 735-737 [Full Text]